Founder of Serum Institute of India - Cyrus Poonawalla owns this publicly listed NBFC

resr 5paisa Research Team 16th December 2022 - 03:12 pm
Listen icon

This NBFC stock has delivered 16% CAGR return over the last 10 years.

According to Forbes rich person list, Cyrus Poonawalla is India’s fifth and world’s 71th richest person. As of August 2, he has a net worth of Rs 1,64,886 crore. He has been awarded with titles like Padma Shri and Padma Bhushan by Government of India.

He is founder of world’s largest vaccine producer (by doses), Serum Institute of India. Serum manufactures roughly 1.5 billion doses of various vaccinations per year, including those for the flu, polio, and measles.

Cyrus is the Managing Director and Chairman of Cyrus Poonawalla Group. The company is headquarted in Pune and holds business interest in diversified sectors like Pharmaceuticals and Biotechnology, Finance, Clean Energy, Hospitality and Realty and Aviation through number of companies operating under the group.

The group includes one publicly listed company – Poonawalla Fincorp Ltd. Poonawalla Fincorp Ltd is a non-banking finance company (NBFC) which specializes in consumer and micro, small and medium enterprise (MSME) financing. The company belongs to BSE group ‘A’ and has a market capitalization of Rs 21,763.20 crore.

The company has an asset under management (AUM) of Rs 17660 crore, which is up 22% YOY and 7% QOQ. The disbursement number for Q1 FY23 also remains strong at Rs 3436 crore, up 98% on YOY basis and 3% on QOQ basis. From Q1 FY22, the average cost of borrowing also fell significantly by 264 basis points in Q1 FY23.

The company has quality management having a strong long-term vision to become India’s top 3 NBFC in consumer and MSME financing.

Talking about shareholding pattern, about 61.49% stake is owned by the promoters, FIIs and DIIs together hold 13.07%, and the rest 25.43% is held by non-institutional investors.

The shares of the company have delivered 16% CAGR returns over the last 10 years. The stock has a 52-week high and low of Rs 343.75 and Rs 141, respectively.

How do you rate this article?

Characters remaining (1500)

Disclaimer: Investment/Trading in securities Market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equites and Derivatives can be substantial.

FREE Trading & Demat Account
+91
''
Resend OTP
''
''
Please Enter OTP
''
By proceeding, you agree T&C*
Mobile No. belongs to